Creating a new imaging agent for prostate cancer that reduces side effects in salivary glands
Official title: The Development of Radiolabeled PSMA Agent with Low Salivary Gland Uptake
Funded at Tripill Biotechnology, Corp. · NIH-10920706 · Data updated 2026-11-12
This study is testing a new treatment for prostate cancer that aims to deliver radiation directly to the tumors while protecting healthy organs, like your salivary glands, to make the treatment safer and more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tripill Biotechnology, Corp. NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $399,981 |
| NIH project number | 1R41CA285188-01A1 |
| Project ID | NIH-10920706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with prostate cancer who are seeking targeted therapies.
✕Less likely to help
Patients with other types of cancer or those who do not have prostate cancer may not benefit from this research.
What this research studies
This research focuses on developing a new radiolabeled agent that targets Prostate Specific Membrane Antigen (PSMA) in prostate cancer while minimizing radiation exposure to normal organs, particularly the salivary glands. The approach involves creating PSMA derivatives that can effectively deliver therapeutic radiation to tumors without harming healthy tissues. By utilizing a trifunctionalized system, the research aims to enhance tumor uptake and reduce side effects, making treatments safer and more effective for patients. The study will involve preclinical testing in rodent models and non-human primates to evaluate the safety and efficacy of the new agent.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for prostate cancer, reducing harmful side effects for patients.
How similar studies have gone: Previous research has shown promise in developing similar theranostic agents, indicating potential for success in this novel approach.
Where this research is happening
-
Tripill Biotechnology, Corp.
Chapel Hill, United States Active
Researchers
- Principal investigator: Wu, Zhanhong — Tripill Biotechnology, Corp.
- Study coordinator: Wu, Zhanhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.